Gerard Marek

Company: Gilgamesh Pharmaceutical

Job title: Chief Medical Officer

Seminars:

Roundtable Discussion | Identifying New Windows of Opportunity for Next-Generation Targets in Depression, Bipolar, PTSD & More 2:00 pm

More practical and highly interactive breakout roundtables where attendees can crowd-source solutions and share opinions around pre-assigned topic areas. Schizophrenia (presented by Nina Dedic) | Other Indications (presented by Gerard Marek) Are there any specific targets showing success in early studies? What are the most promising tools available to aid discovery of new targets? What…Read more

day: Track 1: Discovery & Preclinical

Profiling of a Novel Orally Bioavailable NMDA Receptor Antagonist in Rodents & Humans Demonstrates Value of Translational Biomarkers 11:40 am

In rodents GM-1020 achieves antidepressant-like activity at doses well below those causing motor impairment or disrupting sensory motor processing and has a better therapeutic window than ketamine GM-1020 doses that were antidepressant in rats produced marked effects on EEG power spectrum. In healthy volunteers doses of GM-1020 that produced similar robust effects on EEG were…Read more

day: Track 1 AM Day 1